AHSCT lowers long-term PIRA in aggressive multiple sclerosis
Matched cohort data suggest autologous stem cell transplantation lowers long-term PIRA in aggressive relapsing-remitting multiple sclerosis better than natalizumab-based care.
This section contains the website’s posts.